A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.

Biotechnology

Pharmaceutical

Ratio Therapeutics

Jack Hoppin

Robyn T.

Bill Cupelo

Susan K. Whoriskey

Allan Green

John Babich

Kelly Orcutt

Stephen Dimagno

Matthias Friebe

Shawn Hillier

John M. Garvey

Jacob Hesterman

The Scientific Research Team at Ratio Therapeutics spearheads the development of cutting-edge targeted radiotherapeutics for cancer treatment. Comprising specialists in chemistry, pharmacology, and biology, this team leverages innovative technologies to advance drug discovery and optimize early clinical phase development.

Scientific Research Team

Leadership Team

Operations Team

Scientific Research Team

About

Team members

Other teams at Ratio Therapeutics

Leadership Team

Operations Team